Current Neuropharmacology
August 31, 2026
Harrison J. Elder, Bryan W. Jenkins, C. Austin Zamarripa et al.
Introduction: This narrative review systematically examines the available empirical evidence for interactions between delta-9-tetrahydrocannabinol (Δ9-THC or THC) and C. sativa’s other phytochemical constituents hypothesized to underpin the popular yet controversial notion of ‘entourage effects’ experienced with botanical cannabis. Many relevant preclinical and clinical studies have been...
Zenodo (CERN European Organization for Nuclear Research)
August 11, 2026
Ian Staley
preprint
The QBist and Relational Quantum Mechanics (RQM) informational readings of quantum theory have long lacked a clear account of what kind of physical system qualifies as an “agent” or “observer.” Fuchs, Mermin, and Schack often treat the agent as a human physicist or Bayesian decision-maker; Rovelli suggests that any physical system may serve as a relational observer; Healey abstracts the agent...
Molecular Psychiatry
June 11, 2026
Ritchy Hodebourg, Lillian Duncan, Eric Dereschewitz et al.
The rising legal acceptance of cannabis and the high comorbidity between cannabis use disorder (CUD) and post-traumatic stress disorder (PTSD) highlight the importance of understanding how stress and cannabis influence the brain. We recently discovered that cannabinoid use promotes two PTSD-like symptoms: avoidance coping behaviors and the generalization of stress-coping responses to a neutral...
Clinical Integration and Specialty Practice in Cannabis Nursing
June 5, 2026
Kathleen Marie Pinto Araya
Cannabis use is increasing across the United States, creating clinical, ethical, and educational challenges for Psychiatric-Mental Health Nurse Practitioners (PMHNPs). The evolving legal landscape, including the 2025 federal directive to reclassify cannabis from Schedule I to Schedule III, expands research opportunities while maintaining regulatory complexity. Evidence shows cannabidiol (CBD)...
The American Journal of Medicine
June 2026
Annie Massart, TaRessa Wills, Malavika Kapuria et al.
Cannabis products are widely accessible, yet adult presentations after unintentional ingestion of psychoactive Δ9-tetrahydrocannabinol (THC), synthetic cannabinoids, or adulterated cannabidiol (CBD) remain poorly described. This scoping review summarizes adult unintentional THC exposures among adults seeking medical care with confirmed ingestion, verified either by positive THC urine drug...
European Psychiatry
June 1, 2026
J. Chapelas, L. Costa, M. Alves et al.
Introduction The expanding use of cannabis, in both recreational and medicinal contexts, highlights a dual reality of therapeutic potential and clinical concern. On one side, cannabinoids show promising medical applications, including chronic pain relief and antiemetic effects. On the other, cannabis consumption is linked to a broad spectrum of adverse outcomes. Psychiatric effects range from...
American Journal of Preventive Medicine
May 4, 2026
Kevin H. Yang, Nora Satybaldiyeva, Wayne Kepner et al.
1 citation
IntroductionMicrodosing involves consuming low doses of psychoactive substances, typically between 1/5th and 1/20th of a recreational dose. Despite increasing public attention to cannabis and psychedelics amid evolving drug policies, epidemiologic data on microdosing remain limited.MethodsA cross-sectional, web-based survey (Characterizing the Epidemiology of Cannabidiol Use Survey) of 1,523...
JAMA Internal Medicine
May 1, 2026
Devan Kansagara, Garth E Terry, Chelsea K Ayers et al.
Cannabis use is common among those with mental health conditions, and many people report using cannabis to manage mental health symptoms. It is important for clinicians to understand the lack of clear benefits of cannabis for mental health conditions and the potential for substantial adverse effects. Overall, the potential benefits of cannabis for mental health conditions remain poorly studied....
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
May 1, 2026
Carla Fonseca, F. Gouveia, Soraia Silva et al.
Depression is a highly prevalent and incident mental illness. Current pharmacological therapies fail in approximately 30-40% of patients, highlighting the urgent need for novel agents with pleiotropic effects. This preclinical study aimed to identify new antidepressants and cognitive modulators among five phytocannabinoids: cannabichromene, cannabidiol, cannabidivarin, cannabigerol and...
Neuropharmacology
May 1, 2026
Jairo S Acosta-Vargas, Natalia De Las Heras-Martínez, Alberto Marcos et al.
Cannabis use during adolescence is common and may predispose individuals to substance use disorders. Animal studies have explored the gateway hypothesis, but data on ethanol consumption are limited. This study aimed to investigate the potential link between adolescent cannabis exposure and ethanol self-administration, as well as the relationship between predisposing behavioural traits and...